There’s no denying it; pharma is in its innovation era. The life sciences industry is already undergoing a massive revolution ...

Eran Harary, Senior Vice President of Global Early Clinical Development at Teva, said: “This collaboration will provide ...

The King’s Fund has appointed Siva Anandaciva, its current Chief Analyst, as Director of Policy, Events and Partnerships.

Osivax, a biopharmaceutical company developing vaccines for broad-spectrum protection against infectious viruses, has ...

First patient dosed in phase 1b trial of MB310 therapy Microbiotica, a clinical-stage biopharma company, has announced the dosing of the first patient in its Phase 1b First-in-Human trial, COMPOSER-1, ...

The Scottish Medicines Consortium (SMC) has approved Kite’s CAR T-cell therapy, Yescarta (axi-cel), for treating adult patients with diffuse large B cell lymphoma (DLBCL) and high-grade B-cell ...

The Scottish Medicines Consortium (SMC) has recommended Yselty (linzagolix) for treating moderate to severe symptoms of uterine fibroids (UFs) in women of reproductive age. This decision means ...

A new scientific trial evaluating Bavarian Nordic’s mpox vaccine in pregnant and breastfeeding women and infants is set to launch in the Democratic Republic of Congo (DRC). This research could expand ...

Johnson & Johnson has announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved BALVERSA (erdafitinib) for treating adults with unresectable or metastatic ...

At Blueprint Medicines, we aim to make a significant difference in patients’ lives by solving critical medical problems. Since the company’s inception, we have focused on addressing the burden faced ...

Peace out When Bob Marley sang about ‘so much trouble in t ...